Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC Advertising’s Blurred Line: Rx Spots Look A Lot Like OTC Promotions

This article was originally published in The Tan Sheet

Executive Summary

Competition in the heartburn/GERD category between prescription and OTC drugs illustrates the increasing similarities between over-the-counter and Rx direct-to-consumer advertising

You may also be interested in...

Prilosec OTC Making Inroads Into Abbott’s Prevacid

Abbott Labs plans to counter the launch of Prilosec OTC with a broad direct-to-consumer advertising campaign for its Rx proton pump inhibitor Prevacid

DTC Ad Endorsement Policy Should Be Consistent With OTC Practice – FTC

Endorsements and testimonials in direct-to-consumer advertising for prescription drugs should be subject to the same standards the Federal Trade Commission applies to OTC drug ads, FTC advises in Dec. 1 comments to the agency

GSK Flonase Switch Application Coming? Actual-Use Study Underway

GlaxoSmithKline is actively considering the switch potential for Flonase with a trial evaluating consumers' ability to use the allergy nasal spray appropriately, according to the firm

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts